Haleon plc - ADR

Haleon plc - ADR

HLN

Get informed when a big investor buys or sells

+ Follow
Market Cap$40.79B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Haleon plc - ADRHaleon plc - ADR30.42.04%11%3.30.5

Earnings Call Q4 2025

February 25, 2026 - AI Summary

Organic Sales Growth Guidance: Haleon provided a guidance of 3% to 5% organic sales growth for 2026, indicating a sequential acceleration from the 3% growth achieved in 2025. This outlook is based on expected improvements in the U.S. market and strengthened competitiveness through strategic marketing investments and innovation.
Medium-Term Ambition: The company reiterated its medium-term growth ambition of 4% to 6%, despite experiencing organic sales growth below this range for the past two consecutive years. Confidence in returning to this range stems from expectations of stronger performance in emerging markets, particularly in India and China.
Category Performance: The cold and flu segment is underperforming due to a softer market; however, Haleon is executing plans to improve its Oral Health and Pain Relief categories. Oral Health, bolstered by successful products like Sensodyne and Parodontax, continues to see robust growth while Digestive Health faces challenges, particularly from private label competition.

Exclusive for Stockcircle Pro members

Sign upSign Up
$23.49

Current Fair Value

139.2% upside

Undervalued by 139.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$40.79 Billion
Enterprise Value$48.06 Billion
Dividend Yield$0.19 (2.04%)
Earnings per Share$0.36
Beta0.25
Outstanding Shares4,449,922,000

Return

Return on Equity11.24%ROE
Return on Assets5.66%
Return on Invested Capital10.47%

Valuation & Multiples

P/E Ratio30.42P/E Ratio
PEG30.42PEG
Price to Sales3.27Price to Sales
Price to Book Ratio3.27Price to Book Ratio
Enterprise Value to Revenue3.5
Enterprise Value to EBIT16.6
Enterprise Value to Net Income26
Total Debt to Enterprise0.18
Debt to Equity0.52Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 29, 2026
EPS Estimate
$0.25
Average shareholder expectation
Revenue Estimate
$7.57 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 30, 2026
EPS Estimate
$0.27
Average shareholder expectation
Revenue Estimate
$7.44 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.2237 7.03%
Total Calls51,400 25.62%
Total Puts11,500 8.49%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %12.68% 0.17%
Total Invested$5.68B 0.69%
Investors Holding622 11.00%

ESG Score

No data

About Haleon plc

Relevant Senate Committees

Joint Committee on Taxation

This committee provides crucial analysis and 'revenue estimates' for all tax legislation, directly influencing the tax policies that impact Haleon's financial performance and corporate structure.

Finance

This powerful committee controls taxation and trade policy, directly impacting Haleon's corporate profitability through tax rates and its global supply chain costs through tariffs and trade agreements.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which oversees the approval, labeling, and marketing of many of Haleon's over-the-counter (OTC) drugs, medical devices, and supplements. Labor laws also directly impact its operations.

Judiciary

This committee's oversight of antitrust laws and intellectual property (IP) is critical for Haleon. Antitrust decisions affect mergers and market dominance, while IP protection is vital for its brands and product formulations.